Nephrotic Syndrome
📧 Sign up to get email alerts when something new happens for Nephrotic Syndrome.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2016-11-23Clinical Trial Update: Availability Study of ACTH to Treat Children SRNS/SDNS [NA]
Clinical trial update on an availability study of adrenocorticotropic hormone (ACTH) to treat children with steroid-resistant and steroid-de…
-
CLINICAL_TRIALS research · 2016-11-22Clinical Trial Update: Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD) [Phase 2]
A Phase 2 clinical trial evaluating the combination of rituximab and mesenchymal stem cells for nephrotic syndrome in patients with chronic …
-
FDA approval · 2016-10-07FDA Approved: FUROSEMIDE — Supplemental Application (Marlex Pharmaceuticals, Inc.)
FDA approved a supplemental NDA for furosemide submitted by Marlex Pharmaceuticals, Inc.
-
FDA approval · 2016-09-22FDA Approved: FUROSEMIDE — Supplemental Application (Hospira, Inc.)
FDA approves Hospira, Inc.'s supplemental application for furosemide, initiating a supplemental approval for the drug. The action updates th…
-
FDA approval · 2016-09-19FDA Approved: FUROSEMIDE — Supplemental Application (Phlow Corporation)
FDA approved a supplemental application for furosemide submitted by Phlow Corporation.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2016-09-19FDA Approved: SPIRONOLACTONE — Original Application (Accord Healthcare, Inc.)
FDA approves Accord Healthcare, Inc.'s original application for spironolactone (generic), authorizing its use as a potassium-sparing diureti…
-
CLINICAL_TRIALS research · 2016-08-12Clinical Trial Update: Study of Tacrolimus Used for Pediatric Patients With Nephrotic Syndrome Based on Pharmacogenomics and Metabonomics
Pediatric nephrotic syndrome trial evaluating tacrolimus guided by pharmacogenomics and metabonomics; the study status is currently unknown.
-
FDA approval · 2016-07-20FDA Approved: FUROSEMIDE — Original Application (Amneal Pharmaceuticals LLC)
FDA approved Amneal Pharmaceuticals LLC's original application for furosemide, authorizing a generic version of this diuretic.
-
FDA approval · 2016-06-30FDA Approved: ETHACRYNIC ACID — Original Application (Edenbridge Pharmaceuticals LLC.)
The FDA approved Edenbridge Pharmaceuticals' original application for Ethacrynic acid, a loop diuretic used to treat edema associated with h…
-
CLINICAL_TRIALS trial_result · 2016-04-20Clinical Trial Update: Prospective, Multicenter Study of the Efficacy and Tolerance of Tacrolimus on Refractory Nephrotic Syndrome (RNS) [Phase 3]
A Phase 3 multicenter trial evaluated the efficacy and tolerance of tacrolimus in patients with refractory nephrotic syndrome. The study sta…
-
FDA approval · 2016-03-08FDA Approved: FUROSEMIDE — Supplemental Application (Phlow Corporation)
FDA approved a supplemental application for furosemide submitted by Phlow Corporation.
-
FDA approval · 2016-03-04FDA Approved: LASIX — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for LASIX (furosemide) submitted by Validus Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2016-02-23Clinical Trial Update: Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema [Phase 4]
Phase 4 trial evaluating sequential diuretic therapy with acetazolamide and hydrochlorothiazide followed by furosemide for nephrotic edema. …
-
CLINICAL_TRIALS trial_result · 2016-01-12Clinical Trial Update: Adjusted Steroids Therapy in Childerens With Idiopathic Nephrotic Syndrome [Phase 4]
This document provides a Phase 4 clinical trial update on adjusted steroids therapy for children with idiopathic nephrotic syndrome due to m…
-
CLINICAL_TRIALS trial_result · 2015-12-04Clinical Trial Update: Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis) [Phase 1]
This clinical trial update describes an early-phase study of allogeneic adipose-derived mesenchymal stem cell transplantation for idiopathic…
-
FDA approval · 2015-09-28FDA Approved: BUMEX — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for Bumex (bumetanide) filed by Validus Pharmaceuticals LLC.
-
FDA approval · 2015-08-07FDA Approved: FUROSEMIDE — Supplemental Application (Chartwell RX, LLC)
FDA approved a supplemental application for furosemide submitted by Chartwell RX, LLC.
-
FDA approval · 2015-07-29FDA Approved: ETHACRYNATE SODIUM — Original Application (Par Health USA, LLC)
FDA approved Ethacrynate Sodium as an original ANDA for Par Health USA, LLC.
-
FDA approval · 2015-06-05FDA Approved: FUROSEMIDE — Supplemental Application (Marlex Pharmaceuticals, Inc.)
FDA approved a supplemental NDA for furosemide from Marlex Pharmaceuticals, Inc., updating the product label.
-
CLINICAL_TRIALS trial_result · 2015-05-28Clinical Trial Update: IL-2 for Multi Drug Resistant Nephrotic Syndrome [Phase 1, Phase 2]
A Phase 1/Phase 2 trial evaluating interleukin-2 for multi-drug resistant nephrotic syndrome has completed.
-
CLINICAL_TRIALS trial_result · 2015-05-28Clinical Trial Update: Registry for Patients With Wilms' Tumor Suppressor Gene 1 (WT1) Mutation Associated Diseases
This clinical trial registry update notes the completion of the WT1 mutation–associated disease registry for patients with Denys-Drash syndr…
-
FDA approval · 2015-04-26FDA Approved: SPIRONOLACTONE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Spironolactone from Mylan Pharmaceuticals Inc., indicating an approved change to an already-appr…
-
FDA label_change · 2015-03-30FDA Approved: EDECRIN — Supplemental Application (Bausch Health US, LLC)
FDA approved a supplemental application for EDECRIN (ethacrynic acid) submitted by Bausch Health US, LLC, updating the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2015-01-09Clinical Trial Update: Role of PACAP in Nehprotic Syndrome
This document reports on a completed clinical trial investigating the role of PACAP in nephrotic syndrome. It provides a status update rathe…
-
FDA approval · 2014-10-22FDA Approved: SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for a generic spironolactone and hydrochlorothiazide combination product from Prasco Laboratories.